Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Thyroid Neoplasms × Ropivacaine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Pain, Postoperative 8 Prostatic Neoplasms 4 Pain 4 Agnosia 4 Stomach Neoplasms 3 Lung Neoplasms 3 Postoperative Complications 2 Neoplasms 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Supratentorial Neoplasms 1 Sleep Deprivation 1 Sarcoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Ovarian Cysts 1 Neuroblastoma 1 Neoplasm Metastasis 1 Meningioma 1 Malignant Neoplasms of Male Genital Organs 1 Intraoperative Complications 1 Goiter 1 Ganglion Cysts 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Emergence Delirium 1 Chronic Pain 1

Interventions

Iodine-131 10 Thyrotropin Alfa 7 lenvatinib 6 Sorafenib 6 vandetanib 5 Thyroidectomy 5 Sunitinib 5 Saline Solution 5 pazopanib 4 Triiodothyronine 4 Vemurafenib 3 Thyroxine 3 Paclitaxel 3 Everolimus 3 Dexmedetomidine 3 Control Groups 3 AZD 6244 3 belinostat 2 Trastuzumab 2 Surveys and Questionnaires 2 Surgical Procedures, Operative 2 Immunohistochemistry 2 Gefitinib 2 Calcium Carbonate 2 Bupivacaine 2 Bortezomib 2 Azacitidine 2 Axitinib 2 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2 tumor necrosis factor-alpha, CNGRC fusion protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02112370 2017-08-04

REBT

Seoul National University Hospital

Phase 3 Completed

148 enrolled 17 charts

Goiter, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡